Group items tagged

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

This funding opportunity announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. For the purpose of this FOA, cancers derived from the same organ system (i.e., a group of organs that perform a common function) are considered related. Examples of such organ systems include gastrointestinal, endocrine and other biological systems. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers sustained and promoted by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

 The National Cancer Institute's (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research. 

Roche is pleased to announce that we are accepting applications for the 2013 TCRC Young Investigators Award.  The awards are intended to provide support for the earlier stages of scientific research career development, so they are to be awarded to the employing institutions of promising emerging researchers.  Proposals will be evaluated based on scientific merit and innovation of the projects proposed to be conducted using the awards.   Four awards will be presented on Oct 1, 2013 during the scientific symposium inaugurating Roche's Translational and Clinical Research Center in New York City.   Researchers performing investigations (clinical, in vitro/in vivo or informatics) focused on disease understanding of the following disease areas are encouraged to apply: Cardiovascular & Metabolism - Diabetes and related complications   Neuroscience - Spinal Muscular Atrophy Virology - Influenza Oncology - Treatment and diagnosis of Acute Myeloid Leukemia (AML).

The goal of this Funding Opportunity Announcement (FOA) is to facilitate the planning, designing and initial research focus of Regional Centers of Research Excellence (RCRE) for non-communicable disease, including cancer, in low and middle-income countries (LMICs). 

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research provides funding in a range of areas, including funding for innovative pilot studies, scholar grants to up-and-coming investigators, early detection screening for ovarian cancer, and research symposia on ovarian cancer.

The goal of this Funding Opportunity Announcement (FOA) is to facilitate the planning, designing and initial research focus of Regional Centers of Research Excellence (RCRE) for non-communicable disease, including cancer, in low and middle-income countries (LMICs). Activities in this FOA will be implemented through collaborative partnerships between investigators from institutions in high-income countries (HICs) or upper- middle-income countries (UMICs) and investigators, research administrators, and other stakeholders from LMICs. 

This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. 

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.

This U24 funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative to establish the "NCI Awardee Skills Development Consortium (NASDC)."  The overarching goal of this initiative is to provide opportunities for current NCI grantees, especially those who are junior faculty (e.g., assistant professors, instructors, research scientists, or equivalent), to enhance their skills in areas that are critical for establishing and maintaining successful independent academic cancer research careers. This U24 FOA solicits applications for a Coordinating Center to address the NASDC logistics and evaluation needs in serving the NASDC Research Education Short Courses that will be supported by a companion UE5 FOA (RFA-CA-19-010). 

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to participate in the NIAID Autoimmunity Centers of Excellence (ACE), a cooperative network intended to improve the understanding, prevention, and treatment of autoimmune diseases (www.autoimmunitycenters.org). The ACE was founded on the premise that collaborations among basic and clinical scientists can accelerate both fundamental and applied research. The ACE combines Basic and Clinical research programs. This FOA solicits applications for the Basic research program; a companion FOA solicits applications for the Clinical research program. Members of the Basic research program will conduct innovative studies of human autoimmunity within Principal, Pilot, and Collaborative Projects. Members of the Basic and Clinical ACE will work together to design and conduct studies of autoimmune disease pathogenesis and mechanisms of action of immune-modulating agents being tested in ACE clinical trials.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The purpose of this FOA is to employ immuno-engineering principles to design more durable, widely accessible, and less toxic immunoprevention and immunotherapy strategies. The Immuno-engineering to Improve Immunotherapy (i3) Centers will be comprised of multi-disciplinary teams focused on designing and evaluating innovative engineered immunotherapy approaches and collaborating with the Immuno-Oncology Translational Network (IOTN) investigators to improve existing immunotherapeutic modalities.

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I- Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to two cohorts of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I- Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to two cohorts of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

The goal of the intended FOA is to establish Study Sites for PRS Methods and Analysis for Populations of Diverse Ancestry to collaboratively generate and refine PRS for populations of diverse ancestry by integrating existing datasets with genomic and phenotype data for a range of complex diseases and traits. Together with a Coordinating Center (described in a separate FOA), grantees funded under the intended FOA will form a Consortium with the primary objectives of: 1) leveraging genetic diversity to develop methods and improve the applicability of PRS to predict health and disease risk across diverse populations, and for a broad range of health and disease measures; and 2) optimizing the integration of large-scale, harmonized genomic and phenotype data to facilitate collaborative analysis, dissemination of PRS-related data, and development of related methods and resources.

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this FOA is to establish a Data Management and Resource-sharing Center to provide overall support for the Immuno-Oncology Translational Network (IOTN) and to integrate the research activities of the IOTN with other Cancer Moonshot Initiative programs.

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

The purpose of this Funding Opportunity Announcement (FOA) is to support research on HIV-associated cancers in low- and middle-income countries (LMICs) through collaborative networks between investigators in United States (U.S.) and investigators in LMICs. The FOA solicits applications for Specialized Center Cooperative Agreements (U54) for research on HIV-associated cancers from research institutions in the U.S. and LMICs. Each application is required to propose between one to three research projects that address questions in one theme that are relevant to the LMICs and the U.S. The proposed projects may range, as appropriate, from basic research to translational efforts as well as population and implementation studies; mechanistic clinical studies that meet NIH's definition of a clinical trial will be allowed. In addition, the proposed networks must include two mandatory cores; an Administrative Core and a Developmental Core. Additional cores such as Shared Resource cores may be included as appropriate for the needs of the projects.

The Rivkin Center is announcing funds for Scientific Scholar Awards to be allocated based on scientific merit. Scientific Scholar Awards are intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. The two-year awards will provide a total of $120,000 in funding.